Milestone Scientific, Inc. (NYSE:MLSS) Q3 2020 Earnings Conference Call November 17, 2020 8:30 AM ET Company Participants David Waldman - IR, Crescendo Communications, LLC Leonard Osser - Interim Chief Executive Officer & Director of China Operations Arjan Haverhals - President & Chief Executive Officer of Wand Dental Inc. Joseph D'Agostino - Chief Financial Officer Conference Call Participants Anthony Vendetti - Maxim Group James Terwilliger - Northland Capital Markets Operator Greetings, and welcome to Mi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware 13-3545623 State or other jurisdiction o ...

Milestone Scientific, Inc. (NYSE:MLSS) Q2 2020 Earnings Conference Call August 17, 2020 8:30 AM ET Company Participants David Waldman - IR, Crescendo Communications, LLC Leonard Osser - Interim Chief Executive Officer & Director of China Operations Arjan Haverhals - Chief Executive Officer of Wand Dental Inc. Joseph D'Agostino - Chief Financial Officer Conference Call Participants Anthony Vendetti - Maxim Group James Dowling - Jefferies Capital Operator Greetings. Welcome to the Milestone Scientific Second ...

Sales Performance - The total product sales for the six months ended June 30, 2020, were $1,979,060, a decrease from $4,173,759 in the same period of 2019, reflecting a significant decline in demand due to the COVID-19 pandemic[142]. - Domestic sales in the U.S. for devices dropped to $525 in 2020 from $232,205 in 2019, while handpieces sales decreased to $635,490 from $1,597,316[142]. - International sales for devices were $281,904 in 2020 compared to $665,068 in 2019, and handpieces sales fell to $1,018,123 from $1,485,067[142]. - For the three months ended June 30, 2020, net product sales were $167,674, a decrease of 92.57% compared to $2,257,851 in 2019[144]. - For the six months ended June 30, 2020, total net sales were $1,979,060, a decrease of 52.58% from $4,173,759 in 2019[145]. Profit and Loss - Gross profit for the same period was $112,048, down 92.56% from $1,505,668 in 2019[148]. - Gross profit for the six months was $1,363,734, down 51.35% from $2,802,883 in 2019[154]. - The net loss for the three months ended June 30, 2020, was $3,178,202, compared to a net loss of $1,053,243 in 2019[144]. - The total loss from operations for the six months ending June 30, 2020, was approximately $4.7 million, an increase of 148.26% compared to a loss of $1.9 million in the same period of 2019[157]. Expenses - Selling, general and administrative expenses increased to $3,176,768, a rise of 26.16% from $2,517,970 in 2019[149]. - Research and development expenses for the six months increased to $215,650, a significant rise of 111.68% from $101,875 in 2019[156]. Cash Flow - Cash flow from operating activities for the six months ended June 30, 2020, was a net cash used of $4,111,504, compared to $622,279 in 2019[145]. - Negative cash flows from operating activities for the six months ended June 30, 2020, were approximately $4.2 million, compared to $622,000 for the same period in 2019[158]. - The company had cash and cash equivalents of approximately $16.6 million and working capital of approximately $16.5 million as of June 30, 2020, compared to $1.2 million in working capital on December 31, 2019[158]. Impact of COVID-19 - The COVID-19 pandemic has led to a decrease in demand for the company's products, particularly in the dental and medical divisions, with potential long-term impacts on sales and operations[137]. - The company anticipates that revenue for the third and possibly fourth quarters will be materially and adversely affected due to COVID-19[147]. - The company is focusing on the commercialization of the CompuFlo Epidural System, which may be impacted by the ongoing pandemic[147]. Product Development and Market Expansion - The CompuFlo Epidural System achieved a 99% success rate in identifying the epidural space in a clinical trial involving 400 patients, demonstrating its effectiveness in labor and delivery[130]. - The company has expanded its global footprint by granting exclusive marketing and distribution rights for the Wand/STA Instrument to suppliers in various regions, including Asia, Africa, South America, and Europe[125]. - Milestone Scientific is transitioning from a research and development organization to a commercially focused medical device company following successful FDA clearances of its medical devices[123]. - The company has trained up to 25 exclusive product sales specialists to promote the Wand/STA instrument and handpieces in the U.S. market[123]. - The CompuFlo Epidural Trainer was introduced to the medical education market to improve epidural placement success, with distribution agreements signed with American 3B Scientific[133]. - The company is focused on expanding applications for its DPS Dynamic Pressure Sensing technology platform, aiming to establish it as the standard-of-care in drug delivery[123]. - The CompuFlo Epidural System has obtained FDA clearance, allowing the company to establish distribution in the U.S.[161]. - The company plans to restart the 510K application process for the intra-articular device later this year, subject to available internal resources[161]. Financing Activities - In April 2020, the company completed a Common Stock Offering generating gross proceeds of approximately $5.1 million, followed by a second offering in June 2020 generating approximately $14.6 million[159]. - The combined price of shares and warrants in the April offering was $0.95 per share, while in the June offering it was $2.15 per share[159]. - The company is actively pursuing positive cash flows through increased revenue from its dental and medical devices businesses, while considering other strategic plans[160].

Milestone Scientific, Inc. (NYSE:MLSS) Q1 2020 Results Earnings Conference Call May 18, 2020 8:00 AM ET Company Participants David Waldman - IR, Crescendo Communications, LLC Leonard Osser - Interim Chief Executive Officer, Director of China Operations Joseph D'Agostino - Chief Financial Officer Conference Call Participants Anthony Vendetti - Maxim Group Operator Greetings and welcome to the Milestone Scientific First Quarter 2020 Business Update Conference Call. At this time, all participants are in a list ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2020 Or Commission file number 001-14053 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware 13-3545623 State or other jurisdiction of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware 13-3545623 State or other jurisdictio ...

Milestone Scientific Inc. (NYSE:MLSS) Q3 2019 Results Conference Call November 15, 2019 8:30 AM ET Company Participants David Waldman - IR Len Osser - Interim CEO Joseph D'Agostino - CFO Conference Call Participants Anthony Vendetti - Maxim Operator Good day and welcome to the Milestone Scientific Incorporated Third Quarter 2019 Investor Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Mr. David Waldman, Investor Relations. Please go ahead, sir. David Wal ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended September 30, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) State or other jurisdiction of Incorporation o ...

Milestone Scientific, Inc. (NYSE:MLSS) Q2 2019 Results Conference Call August 16, 2019 8:30 AM ET Company Participants Natalya Rudman - Investor Relations Leonard Osser - Interim Chief Executive Officer Joseph D'Agostino - Chief Financial Officer Conference Call Participants Anthony Vendetti - Maxim Group Tony Kamin - Eastwood Partners Operator Good day and welcome to the Milestone Scientific Second Quarter 2019 Investor Call. Today's conference is being recorded. At this time, I would like to turn the conf ...